
Boosting the Drug Development Process with Emerging Technologies
In the past, most drugs have been found by either identifying the active ingredient from traditional remedies or finding it serendipitous. The drug discovery process involves patient identification, synthesis, characterization, screening, and therapeutic effectiveness testing. A new team of scientists led by the University of California, Los Angeles (UCLA) has developed a new technique that helps researchers to find out the structures of organic molecules easily and quickly with the very small samples.
The work is already attracting considerable attention in the science community: A sample copy of the paper posted on the ChemRxiv website has been downloaded 19,000 times in just one day, which broke the previous record of 15,000 times downloads in six months, according to a report in ACS Central Science.
Check out: Top Pharmacy Management Tech Companies
The final paper, published in ACS Central Science, illustrates a new method for examining small molecules with the help of electron microscopes. This approach allows scientists to analyze nanocrystals, that are so small that they can be only seen using special electron microscopes, and to identify them within approximately 30 minutes instead of several hours.
In recent years, affinity chromatography for the separation and analysis of biomolecules based on their biological functions or individual pharmaceutical, biochemical, biotechnological, and environmental sciences structures, has become increasingly important and useful. If a ligand is immobilized on a polymer carrier, usually by covalent coupling, and filled in a column, the ligand-related substances can be separated from other substances.
Ultimately, the technique is successful to speed up drug development processes because pharmaceutical companies are able to screen more samples faster than ever, reducing the time it takes to verify the molecular structure of potential drugs.
Biochemical suppression involves adding a small molecule to protein extracts, which inhibits an activity test. First, a protein extract is mixed with a molecule that inhibits interesting activity. An uninhibited protein extract is then divided into the inhibited extract and determined whether any fraction suppresses the inhibition. If a fraction is found that suppresses the inhibitory activity of the small molecule, further fractionation rounds are carried out to purify the activity of the suppressor. The new scientific approaches have therefore significantly improved the predictability of the number of drug targets and their responses to natural or synthetic ligands
Few Pharmacy Management Companies - AscellaHealth, Delta Care Rx, Micro Merchant Systems,...
ON THE DECK
Featured Vendors
Tenthpin: The Trusted Advisor for Data-Driven Patient- Centric Value Chain Management in Life Sciences
Process Stream: Into the Depths: How Process Stream Leverages Experience and Embedded Research to Transform Businesses from the Inside Out
Indegene: Leveraging Technology to Drive Growth and Productivity Investing In Innovation In Operations, Analytics and Clinical Technology
MMIS: Global Compliance Platform Streamlines Processes and Delivers Business Intelligence Enterprise-Wide
Acceliant: Leading with Innovation, Facilitating Collaboration, Standardization and Productivity in Clinical Trial Management
Saama Technologies: New Fluid Analytics Engine from Saama Cost-Effectively and Rapidly Resolves Complex Data Analytics Challenges for Life Sciences
Iris Interactive Corporation: Boosting Collaboration and Decision Making Processes to Bring Products
Techsol Corporation: Offering Domain Rich, Regulatory Compliant, Accelerated and Cloud Enabled Techn
Solea Software Solutions: Offering Business Intelligence, Analytics, and Portal Services for Flouris
Xybion Corporation: Providing Interconnected Technology Enabled Solutions for Life Sciences, and other Highly Regulated Industries
EDITOR'S PICK
Essential Technology Elements Necessary To Enable...
By Leni Kaufman, VP & CIO, Newport News Shipbuilding
Comparative Data Among Physician Peers
By George Evans, CIO, Singing River Health System
Monitoring Technologies Without Human Intervention
By John Kamin, EVP and CIO, Old National Bancorp
Unlocking the Value of Connected Cars
By Elliot Garbus, VP-IoT Solutions Group & GM-Automotive...
Digital Innovation Giving Rise to New Capabilities
By Gregory Morrison, SVP & CIO, Cox Enterprises
Staying Connected to Organizational Priorities is Vital...
By Alberto Ruocco, CIO, American Electric Power
Comprehensible Distribution of Training and Information...
By Sam Lamonica, CIO & VP Information Systems, Rosendin...
The Current Focus is On Comprehensive Solutions
By Sergey Cherkasov, CIO, PhosAgro
Big Data Analytics and Its Impact on the Supply Chain
By Pascal Becotte, MD-Global Supply Chain Practice for the...
Technology's Impact on Field Services
By Stephen Caulfield, Executive Director, Global Field...
Carmax, the Automobile Business with IT at the Core
By Shamim Mohammad, SVP & CIO, CarMax
The CIO's role in rethinking the scope of EPM for...
By Ronald Seymore, Managing Director, Enterprise Performance...
Driving Insurance Agent Productivity with Mobile and Big...
By Brad Bodell, SVP and CIO, CNO Financial Group, Inc.
Transformative Impact On The IT Landscape
By Jim Whitehurst, CEO, Red Hat
Get Ready for an IT Renaissance: Brought to You by Big...
By Clark Golestani, EVP and CIO, Merck
Four Initiatives Driving ECM Innovation
By Scott Craig, Vice President of Product Marketing, Lexmark...
Technology to Leverage and Enable
By Dave Kipe, SVP, Global Operations, Scholastic Inc.
By Meerah Rajavel, CIO, Forcepoint
AI is the New UI-AI + UX + DesignOps
By Amit Bahree, Executive, Global Technology and Innovation,...
Evolving Role of the CIO - Enabling Business Execution...
By Greg Tacchetti, CIO, State Auto Insurance